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Background {#Sec2}
==========

In humans, the spleen is the largest secondary immune organ in the body. Important functions of the spleen include removal of old and abnormal blood cells, removal of circulating pathogens, and facilitating the development of immune responses against *Plasmodium* \[[@CR1]\]. It has been shown that the spleen plays an active role in the retention and removal of malaria-infected red blood cells (RBCs) from blood circulation, as well as a key role in the development of immune responses directed against parasites \[[@CR2]\]. Parasite clearance rates are influenced by many factors, including insufficient artesunate and dihydroartemisinin levels in the blood, pharmacokinetics, pharmacodynamics, splenectomy, hemoglobin abnormalities, and reduced immunity, which may delay parasite clearance \[[@CR3], [@CR4]\]. The World Health Organization's (WHO's) classification of antimalarial drug efficacy (parasitemia on Day three with axillary temperature ≥ 37.5 °C) \[[@CR5]\] may not apply to asplenic patients. This paper reports a case of prolonged parasite clearance in a splenectomized Chinese worker with falciparum malaria imported from Nigeria.

Case presentation {#Sec3}
=================

A 35-year-old Chinese male was admitted to the 6^th^ People's Hospital in Zhengzhou, China on October 6, 2014, because he had a fever with the highest axillary temperature of 40 °C, headache, and chills. Prior to admission, the patient had suffered 2 days of febrile illness after returning from Nigeria on October 1, 2014. The patient had not used chemoprophylaxis against malaria in Nigeria when he worked there as a construction worker between 2009 and 2014. The patient had three episodes of malaria and had been administrated quinine, but stopped treatment as soon as he was afebrile. The patient also had a splenectomy due to a traffic accident 8 years ago from the time he was admitted to hospital.

Upon admission, the patient's axillary temperature was 37.2 °C, his pulse rate was 75 beats/min, his blood pressure was 93/79 mmHg, and his weight was 86 kg. Initial laboratory test results were almost normal except for a high C-reactive protein level of 35.8 mg/L and a low kalaemia level of 3.30 mmol/L (see Table [1](#Tab1){ref-type="table"}). Giemsa-stained thick and thin blood films were microscopically examined and the peripheral blood smear showed parasitaemia of *Plasmodium falciparum*. Microscopy experts at the Henan Center for Disease Control and Prevention confirmed this result. The density of malarial parasites was 53 913 asexual parasites/μl on Day 0. A rapid diagnostic test (Wondfo Biotech Co., Ltd, China) was also positive for malarial antigen. DNA of *P. falciparum* was identified by nested polymerase chain reaction (PCR) amplification of the small-subunit ribosomal ribonucleic acid (18ssrRNA) genes. The K13 propeller gene was amplified using nested PCR and sequenced. No mutations were found when this gene was compared to the PF3D7_1343700 K13 propeller gene reference sequence retrieved from the National Center for Biotechnology Information (NCBI) database.Table 1Pre-treatment blood resultVariableValueReference value*Hematology*Leukocytes6.93 × 10^9^/L4--10 × 10^9^/LNeutrophil84.11%45 \~ 77%Lymphocyte10.52%20--40%Monocyte4.50%3--8%Eosinophil0.60%0.5--5%Basophil0.30%0--1%Erythrocytes5.08 × 10^12^/L3.5--5.5 × 10^12^/LHemoglobin155 g/L110--160 g/LHematocrit46%36--50%Platelets192 × 10^9^/L100--300 × 10^9^/LHCT46.4036.6--50%MCV89.7086--100 flMCH30.8026--31 pgMCHC343.00310--370 g/L*Blood chemistry*AST18 IU/L\<40ALT40 IU/L\<40LDH151 IU/L110--240γ-GTP47 IU/L\<40Total bilirubin14.2 μmol/L3.0--21.0BUN4.5 mmol/L3.2--7.1Creatinine91 μmol/L44--133Uric acid282 μmol/L201--430Sodium134 mmol/L135--145Potassium3.30 mmol/L3.5--5.5Chloride97 mmol/L98--110CRP35.8 mg/L0.10--8.20*Abbreviations*: *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *BUN* blood urea nitrogen, *CRP* C-reactive protein, *HCT* Hematocrit, *LDH* lactic dehydrogenase, *MCH* mean corpuscular hemoglobin, *MCHC* mean corpuscular hemoglobin concentration, *MCV* erythrocyte mean corpuscular volume, *γ-GTP* gamma-glutamyl transpeptidase

The patient was intravenously administered artesunate (120 mg first time; then 60 mg every six hours) for 4 days and intravenously treated with the antibiotic ceftriaxone (2.0 g per day) for 4 days. After 72 hours of treatment, the axillary temperature of the patient was 37.4 °C and the density of falciparum parasites was 26 674 asexual parasites/μl (see Table [2](#Tab2){ref-type="table"}). The patient was continuously intravenously administered artesunate (60 mg every 8 h for 9 days; 60 mg every 12 h for 1 day; 60 mg every day for 4 days) with antibiotic ceftriaxone of 2.0 g per day for 14 days. The patient was afebrile on Day 4 but blood microscopy revealed the continuous presence of parasitaemia with densities between 16 133 and 34 356 asexual parasites/μl. The patient was orally administrated dihydroartemisinin-piperaquine (40 mg/0.32 g per tablet, two tablets twice per day) for 2 days from Day 10. The parasitemia declined slowly and morphology of the parasites in the blood films, with pyknotic nuclei and shrunken cytoplasm, suggested that they were dead. Falciparum parasitaemia was negative on Day 21. The patient was cured and left hospital on Day 24 after no plasmodium falciparum was found in the blood on Day 21 to Day 23.Table 2Parasite density and body temperature of patient during hospital stayDayTemperature (°C)Parasite density (asexual parasites/μl)037.253 913137.030 581237.730 545337.426 674436.534 356536.631 701636.223 896736.525 316837.221 982937.516 1331037.519 8471136.5--1237.216 4341336.3--1436.22 9621536.3--1636.23 2111736.3--1836.72 6881935.9--2036.73642136.502236.002336.40

Discussion {#Sec4}
==========

Malaria had a wide geographical distribution in China but this has decreased dramatically due to the strengthening of malaria control measures in recent decades, especially in the Yunnan and Hainan provinces, and Huanghuai region \[[@CR6]--[@CR8]\]. No locally transmitted malaria cases have been reported since 2012, but imported malaria has increased remarkably in Henan, which may cause secondary spread and antimalarial drug resistance. In 2014, 216 imported malaria cases were reported, which was 24 times higher than the nine imported cases in 2005 in this province \[[@CR9]\]. With increasing travel and migration, imported malaria has become a major public health challenge \[[@CR10]--[@CR12]\] and poses a severe threat to the malaria elimination program in China \[[@CR13]\]. The WHO currently recommends artemisinin-based combination therapies (ACTs) as the first-line treatment for uncomplicated *P. falciparum* malaria \[[@CR14]\], and oral dihydroartemisinin-piperaquine tablets are most commonly used in China \[[@CR15]\]. Typically, a 3-day treatment course with an ACT reduces parasite densities and 95% of patients' malaria blood slide test results are negative 48 h after treatment \[[@CR16]\]. The emergence of artemisinin resistance, evidenced by delayed parasite clearance after artemisinin treatment, poses a serious threat to the global control of malaria. Artemisinin resistance is characterized by a reduced susceptibility of the ring stage of parasite development. It was first documented in western Cambodia \[[@CR17], [@CR18]\] and is now prevalent across an expanding area of Southeast Asia, including in Cambodia \[[@CR19]--[@CR21]\], Thailand \[[@CR22], [@CR23]\], and the Thai-Myanmar border \[[@CR24]\].

Over the past decade, African countries have transitioned from using chloroquine or sulfadoxine-pyrimethamine to ACTs as a first-line policy for treating uncomplicated malaria \[[@CR25]\]. Although ACT-resistant malaria is rare in Africa, there is a historical precedence of resistance to antimalarial medicine emerging in Asia and spreading to Africa \[[@CR26]\]. Three cases of early treatment failure due to possible ACT-resistant *P. falciparum* malaria have been reported in Nigeria \[[@CR27]\]. There has also been a case of possible artemether-lumefantrine treatment failure in an Italian traveler with uncomplicated *P. falciparum* malaria imported from the Democratic Republic of the Congo \[[@CR28]\]. Routine monitoring is needed to ensure that the recommended first-line ACTs are effective for timely changes in national treatment policies and for the early detection of artemisinin resistance.

Prolonged parasite clearance is the basis for the current WHO working definition of artemisinin resistance \[[@CR5]\] but it may not applicable for patients who have had a splenectomy \[[@CR29]--[@CR31]\]. In the case reported in this paper, blood microscopy revealed that falciparum parasitemia was continuously present and was negative on Day 20 after artemisinin treatment. According to the WHO classification of antimalarial drug efficacy (parasitemia on Day three with axillary temperature ≥ 37.5 °C) \[[@CR5]\], the patient was considered an early treatment failure for the first time in China. Actually, it is caused by splenectomy but not artemisinin resistance.

The spleen is responsible for initiating immune reactions to blood-borne antigens and for filtering the blood of foreign material, and old or damaged RBCs. It plays a crucial role in the defense against infections with viruses, bacteria, fungi, and parasites \[[@CR32]\]. The spleen plays a pivotal role in the rapid clearance of parasitized RBCs in patients with falciparum malaria after artemisinin treatment, and parasite clearance after artesunate treatment can be markedly prolonged in falciparum malaria patients who have had a splenectomy \[[@CR33]\]. A previous study showed that *Plasmodium*-infected erythrocytes lose their normal deformability and become susceptible to splenic filtration, and splenic clearance of erythrocytes is enhanced by antimalarial therapy and splenomegaly \[[@CR34]\]. The intact splenic function is of utmost importance for the host's defense capacity against *Plasmodium* spp., not only because it limits the acute infection through the removal of parasites from the blood stream, but also because it modulates parasite antigen expression on the surface of infected RBCs as well as cellular and humoral immune responses \[[@CR35]\]. Other causes of immune suppression, such as cancer, may possibly reactivate latent malaria parasites \[[@CR36]\]. Falciparum malaria infection is common in pregnant women and anemia is an important complication \[[@CR37]\]. HIV infection may defects in macrophage phagocytosis, which diminish the spleen's ability to clear infection, causes the rapid onset of cerebral malaria in children \[[@CR38]\].

The delay in parasite clearance has also been reported in a splenectomized patient with *P. knowlesi* malaria \[[@CR39]\]. In a prospective controlled study of 33 previously splenectomized Malawian adults, parasite densities of *P. falciparum* reached significantly higher levels, and mature parasite stages were more often seen in the peripheral blood of asplenic individuals \[[@CR40]\]. In areas endemic for *P. falciparum*, fever and parasitemia are significantly more frequent in splenectomized patients than in spleen-intact patients \[[@CR40]--[@CR42]\]. Splenectomized patients are at high risk of developing a more severe and fatal disease, even if they acquired semi-immunity prior to the loss of splenic tissue \[[@CR29], [@CR33], [@CR35], [@CR43]\]. In this case, the patient's main symptoms were fever and parasitemia. The parasitemia declined slowly following artemisinin treatment. The morphology of the parasites in the blood films, with pyknotic nuclei and shrunken cytoplasm, suggested that they were dead. Although drug-affected parasites have clearly abnormal shapes, it is not easy to distinguish live parasites from dead ones. Malaria parasites were observed in blood films until Day 21 after continuous artemisinin treatment. Chotivanich et al. reported that patients without a functional spleen who have prolonged parasite clearance presumably do not require additional antimalarial treatment \[[@CR33]\].

Recently, a molecular marker of artemisinin resistance was identified. Mutations in K13 propeller domain were shown to be associated with delayed parasite clearance in vitro and in vivo \[[@CR44], [@CR45]\]. The detection of molecular mutations associated with K13 will greatly facilitate the tracking of artemisinin resistance as it emerges. In the case reported in this paper, prolonged parasite clearance was found after treatment with artesunate and ACT. The patient had a splenectomy due to a traffic accident 8 years ago from the time he was admitted to hospital and no mutation was found in the K13 propeller gene. Therefore, this case was finally identified as prolonged parasite clearance by splenectomy.

Conclusion {#Sec5}
==========

This paper reports a case of prolonged parasite clearance in a splenectomized Chinese worker with falciparum malaria imported from Nigeria. Artemisinin resistance should be distinguished when prolonged parasite clearance is found in a malaria patient who has had splenectomy.
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